Details
Stereochemistry | ACHIRAL |
Molecular Formula | C11H12N4O3S |
Molecular Weight | 280.3045 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COc1cnc(nc1)NS(=O)(=O)c2ccc(cc2)N
InChI
InChIKey=GPTONYMQFTZPKC-UHFFFAOYSA-N
InChI=1S/C11H12N4O3S/c1-18-9-6-13-11(14-7-9)15-19(16,17)10-4-2-8(12)3-5-10/h2-7H,12H2,1H3,(H,13,14,15)
Molecular Formula | C11H12N4O3S |
Molecular Weight | 280.3045 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment:: description was created based on several sources, including:
http://www.sigmaaldrich.com/catalog/product/sigma/s0383?lang=es®ion=ES
http://www.medchemexpress.com/sulfameter.html
Curator's Comment:: description was created based on several sources, including:
http://www.sigmaaldrich.com/catalog/product/sigma/s0383?lang=es®ion=ES
http://www.medchemexpress.com/sulfameter.html
Sulfametoxydiazine (INN) or sulfamethoxydiazine (USAN: sulfameter) is a long-acting sulfonamide antibacterial, shows bacteriostatic effects against Gram positive and Gram negative bacteria in vivo. It is used as a leprostatic agent and in the treatment of urinary tract infections. Orally active. Sulfonamides block the synthesis of dihydrofolic acid by inhibiting the enzyme dihydropteroate synthase. Sulfonamides are competitive inhibitors of bacterial para-aminobenzoic acid (PABA), which is required for bacterial synthesis of folic acid. Sulfameter is a dihydrofolate reductase (DHFR) inhibitor. Mode of resistance is via the alteration of dihydropteroate synthase or alternative pathway for folic acid synthesis.
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
44.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5072410/ |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
SULFAMETER plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1599 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5072410/ |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
SULFAMETER plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
24 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/5072410/ |
1 g single, oral dose: 1 g route of administration: Oral experiment type: SINGLE co-administered: |
SULFAMETER plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
250 mg/kg 1 times / day steady, oral Recommended Dose: 250 mg/kg, 1 times / day Route: oral Route: steady Dose: 250 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 20 Health Status: unhealthy Condition: chronic urinary-tract infection Age Group: adult Sex: unknown Population Size: 20 Sources: |
|
500 mg/kg 1 times / day steady, oral Recommended Dose: 500 mg/kg, 1 times / day Route: oral Route: steady Dose: 500 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 43 Health Status: unhealthy Condition: pustular acne vulgaris Age Group: adult Sex: unknown Population Size: 43 Sources: |
Disc. AE: Nasal stuffiness, Edema lip... AEs leading to discontinuation/dose reduction: Nasal stuffiness (2 patients) Sources: Edema lip (1 patient) Leukopenia (1 patient) |
2 g single, oral Studied dose |
healthy, adult n = 6 Health Status: healthy Age Group: adult Sex: unknown Population Size: 6 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Edema lip | 1 patient Disc. AE |
500 mg/kg 1 times / day steady, oral Recommended Dose: 500 mg/kg, 1 times / day Route: oral Route: steady Dose: 500 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 43 Health Status: unhealthy Condition: pustular acne vulgaris Age Group: adult Sex: unknown Population Size: 43 Sources: |
Leukopenia | 1 patient Disc. AE |
500 mg/kg 1 times / day steady, oral Recommended Dose: 500 mg/kg, 1 times / day Route: oral Route: steady Dose: 500 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 43 Health Status: unhealthy Condition: pustular acne vulgaris Age Group: adult Sex: unknown Population Size: 43 Sources: |
Nasal stuffiness | 2 patients Disc. AE |
500 mg/kg 1 times / day steady, oral Recommended Dose: 500 mg/kg, 1 times / day Route: oral Route: steady Dose: 500 mg/kg, 1 times / day Sources: |
unhealthy, adult n = 43 Health Status: unhealthy Condition: pustular acne vulgaris Age Group: adult Sex: unknown Population Size: 43 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia. | 1996 Apr |
|
Hydrogen bonding in sulfonamides. | 2001 Dec |
|
[Qualification and quantification of 10 sulfonamides in animal feedstuff by high performance liquid chromatography-electrospray tandem mass spectrometry]. | 2005 Jul |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Hapten synthesis and development of polyclonal antibody-based multi-sulfonamide immunoassays. | 2006 Jun 28 |
|
Analytical methods for multiresidue determination of sulfonamides and trimethoprim in meat and ground water samples by CE-MS and CE-MS/MS. | 2007 Nov |
|
Desolvation kinetics of sulfameter solvates. | 2008 Jun |
|
[Simultaneous determination of sulfonamides and fluoroquinolones residues in chicken by high performance liquid chromatography-electrospray tandem mass spectrometry]. | 2008 May |
|
Determination of 76 pharmaceutical drugs by liquid chromatography-tandem mass spectrometry in slaughterhouse wastewater. | 2009 Nov 20 |
|
A new and simple method to determine trace levels of sulfonamides in honey by high performance liquid chromatography with fluorescence detection. | 2009 Oct 23 |
Patents
Sample Use Guides
Loading dose first-day only (single dose): 1500 mg (3 tablets)
Daily maintenance (single dose at 24 hour intervals): 500 mg (1 tablet).
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14296029
Titrations of antibacterial activity were carried out by making twofold serial dilutions dilutions of plasma or serum and adding an equal volume (0.5 ml.) of a 10-5 dilution of an overnight culture of a strain of Escherichia coli which had been isolated from the peritoneal fluid of a patient with peritonitis and which was consistently sensitive to 0.30 mg. of sulfamethoxydiazine per 100 ml. of broth. Study of antibacterial titers showed that at 1: 64 the sulfonamide concentrations varied from 7 to 14 mg. per 100 ml
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:54:52 UTC 2021
by
admin
on
Fri Jun 25 21:54:52 UTC 2021
|
Record UNII |
3L179F09D6
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J01ED04
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
||
|
NCI_THESAURUS |
C29739
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C66568
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY | |||
|
2511
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY | |||
|
651-06-9
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY | |||
|
211-480-8
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY | |||
|
M10316
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY | Merck Index | ||
|
651-06-9
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY | |||
|
3L179F09D6
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY | |||
|
5326
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY | |||
|
D013417
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY | |||
|
CHEMBL1200359
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY | |||
|
SULFAMETOXYDIAZINE
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY | |||
|
DB06821
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY | |||
|
SUB10714MIG
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY | |||
|
1335
Created by
admin on Fri Jun 25 21:54:52 UTC 2021 , Edited by admin on Fri Jun 25 21:54:52 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |